Actively Recruiting

Age: 18Years +
All Genders
NCT06093022

Surgical or Medical Treatment of Breast Cancer Metastasis: A Multicentre Observational Study

Led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Updated on 2023-11-14

720

Participants Needed

1

Research Sites

561 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The liver represents the third most common site of breast cancer (BC) metastases behind the lymphatics and bone. The primary treatment for BCLM remains chemo-therapy and, more recently, targeted immunotherapy. The role of liver resection in BCLM remains controversial. The primary aim of the study is to compare the efficacy of liver resection vs. medical therapy alone in Breast Cancer Liver Metastasis (BCLM) patients.

CONDITIONS

Official Title

Surgical or Medical Treatment of Breast Cancer Metastasis: A Multicentre Observational Study

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age over 18 years
  • Diagnosis of breast cancer liver metastases (BCLM)
  • Presence of BCLM with or without disease outside the liver
  • Any treatment received for BCLM
  • Ability to understand and sign informed consent
Not Eligible

You will not qualify if you...

  • Unable to provide informed consent
  • Patients who have received only best supportive care or palliative care

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome, Lazio, Italy, 00168

Actively Recruiting

Loading map...

Research Team

A

Amelia Mattia, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here